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Purpose: To evaluate the efficacy of minimal stimulation using discretely adminis-
tered gonadotropin combined with clomiphene citrate (CC) or letrozole (LTZ) for 
intrauterine insemination (IUI) cycles. Materials and Methods: Total 257 IUI cy-
cles from 158 infertile couples were assessed. A CC dose of 100 mg/day (n=126 
cycles) or a LTZ dose of 5 mg/day (n=131 cycles) was administered on days 3‒5 of 
the menstrual cycle for 5 days. Each group received human menopausal gonadotro-
pin at a dose of 150 IU by two or three alternative day: CC combined with alter-
nate-day regimen for 2 or 3 days (CC+300, n=37; CC+450, n=89) and LTZ com-
bined with alternate-day regimen for 2 or 3 days (LTZ+300, n=36; LTZ+450, 
n=95). Results: The clinical pregnancy rate was comparable between the CC and 
LTZ groups (18.3% vs. 13.0%, p=0.243). The clinical pregnancy rate also showed 
no significant difference among the 4 groups (21.6% vs. 16.9% vs. 11.1% vs. 
12.6%, p=0.507). The multiple pregnancy rate was significantly higher in LTZ 
compared to CC group (37.5% vs. 8.7%, p=0.028) and in the LTZ+450 compared 
to CC+450 group (50% vs. 13.3%, p=0.038). Overall, there were 15 cases of ovari-
an hyperstimulation syndrome (OHSS), with the prevalence being significantly 
lower in the LTZ compared to CC group (1.5% vs. 10.3%, p=0.003). OHSS was 
more prevalent in the CC+450 compared to the LTZ+450 group (12.4% vs. 1.1%, 
p=0.002). Conclusion: Our findings suggest that minimal stimulation using two al-
ternate-day gonadotropin with LTZ decreases the development of OHSS and multi-
ple pregnancies, while maintaining comparable pregnancy rates in IUI cycles.
Key Words:   Intrauterine insemination, minimal stimulation, gonadotropin, letro-
zole, clomiphene citrate
INTRODUCTION
In subfertile couples, intrauterine insemination (IUI) is often a stop gap treatment 
while waiting for, or instead of in-vitro fertilization (IVF). Although IUI has not 
been included as an assisted reproductive technique, it has been widely applied em-
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Only patients aged 25‒42 years with at least one patent 
tube were included in this study. The indications for treat-
ment were unexplained infertility, endometriosis or male 
factor infertility. While most couples had a duration of in-
fertility ≥1 year and underwent a routine infertility workup, 
some of them had a duration <1 year, with participating 
women being aged >35 years. The following exclusion cri-
teria were adopted: bilateral tubal obstruction, stage III‒IV 
endometriosis, cycles using donor sperm, previous IUI at-
tempts 4 or more, and cycles cancelled due to no ovarian 
response to ovarian stimulation. This study was approved 
by the Institutional Review Board at the Severance Hospi-
tal, Yonsei University College of Medicine.
All women underwent testing for tubal patency by hys-
terosalpingography, evaluation of pelvic anatomy by trans-
vaginal ultrasound, and assessment of basal hormones on 
day 3 of the menstrual cycle. Semen parameters were inter-
preted using the World Health Organization (2010) criteria. 
The regimen of ovulation induction was determined based 
on the previous response or physician’s preference. A dose 
of 100 mg/d CC (Clomiphene, Youngpoong Pharma, Seoul, 
Korea) or 5 mg/d LTZ (Femara, Novartis, Basel, Switzer-
land) was administered on days 3‒5 of the menstrual cycle 
for 5 days. In combination with their fixed schedule for CC 
or LTZ, patients received two different regimens of hMG, 
(IVF-M, LG Life Sciences, Seoul, Korea), either 150 IU 
administered on day 6 and 8 of the menstrual cycle (2-day 
regimen, on alternate days) or 150 IU administered on days 
5, 7, and 9 of the menstrual cycle (3-day regimen, on alter-
nate days). A total of 257 cycles were divided into 2 main 
groups based on the fixed schedule treatment: the CC group 
(n=126) or LTZ group (n=131). Each group was further di-
vided into two subgroups according to the alternate-day reg-
imen of gonadotropin used: CC combined with a 2-day regi-
men (CC+300 group, n=37) or 3-day regimen (CC+450 
group, n=89), and LTZ combined with a 2-day regimen 
(LTZ+300 group, n=36) or 3-day regimen (LTZ+450 
group, n=95). The luteinizing hormone (LH) surge was 
tested using LH2 kits (Bayer Corporation, Tarrytown, NY, 
USA). When the mean diameter of the leading follicle 
reached 17‒18 mm, an injection of 10000 IU of urinary hu-
man chorionic gonadotropin (hCG) (IVF-C, LG Life Sci-
ences, Seoul, Korea) or 250 µg of recombinant hCG (Ovi-
drel, Serono, Geneva, Switzerland) was administered 
intramuscularly or subcutaneously. IUI was performed 38 h 
after hCG administration. If the urinary LH surge test was 
positive, the insemination was performed the day after de-
pirically.1,2 However, the superiority of IUI compared to that 
of IVF or efficacy of IUI compared to that of expectant man-
agement is debatable. In 2009, the European Society of Hu-
man Reproduction and Embryology Capri Workshop Group 
reviewed controversies in IUI on the basis of the available 
evidence.3 They suggested that compared to expectant man-
agement, IUI with stimulation might lead to improved clinical 
outcomes.4,5 Particularly, ovarian stimulation with gonadotro-
pin may have a moderate benefit compared to clomiphene ci-
trate,5,6 while still being associated with increased cost for the 
repeated injections, frequent monitoring, risk of multiple 
pregnancies7-9 and development of ovarian hyperstimulation 
syndrome (OHSS) as a complication.10,11 
The most desirable goal of ovulation induction for IUI is a 
higher pregnancy rate with reduced complications. To achieve 
this goal, the use of minimal stimulation has been consid-
ered, because it has been reported to reduce complications 
while maintaining overall pregnancy rates.12 The concept of 
minimal stimulation was first proposed by Kistner in 1972, 
who used clomiphene citrate (CC) followed by overlapping 
human menopausal gonadotropin (hMG) to increase the 
pregnancy rate compared to the use of CC alone and to re-
duce the amount of hMG required for stimulation. Since 
then, research has continued using variable agents combined 
with various doses and types of gonadotropin. In spite of the 
heterogeneity of previous studies‒ranging from retrospective 
reviews to prospective randomized controlled studies‒inves-
tigating minimal stimulation, the clinical pregnancy rates re-
ported were equal or superior to those in gonadotropin-only 
regimens.13,14 Furthermore, the use of minimal stimulation re-
sulted in fewer stimulation days and less gonadotropin use, 
suggesting that it is more cost-effective than gonadotropin-
only cycles .10,15-17
Although previous studies have reported comparable preg-
nancy outcomes for IUI using minimal stimulation,6,12-14,18 
there is lack of evidence regarding the regimen to be selected 
in the clinical field. This study aimed to identify an effica-
cious regimen for discrete administration of gonadotropin 
combined with CC or letrozole (LTZ), to be used in ovula-
tion induction for IUI.
MATERIALS AND METHODS
The present study was designed as a retrospective compara-
tive study. From January 2008 to March 2013, 257 IUI cy-
cles performed in 158 couples were included in this study. 
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version 20.0 (IBM Inc., Armonk, NY, USA) by Student t-
test and one-way ANOVA to compare means for normally 
distributed continuous variables. The Mann-Whitney U test 
was used for non-parametrically distributed variables. Fish-
er’s exact test and the chi-square test were used for categor-
ical variables. Univariate and multivariate logistic regres-
sion analyses were also performed. Sample size calculation 
was not performed since the study was designed as retro-
spective comparative study based on chart review. A p val-
ue <0.05 was considered statistically significant.
RESULTS
 
There were no significant differences between the 4 groups 
in terms of the women’s age, duration of infertility, percent-
age of primary infertility, causes of infertility, and tubal pa-
tency. However, there was a significant difference in basal 
serum follicle-stimulating hormone (FSH) levels among the 
4 groups, with the post hoc analysis showing significantly 
higher basal serum FSH levels in the LTZ+450 group com-
pared to the CC+300 group (6.66±2.09 vs. 8.75±3.81, p= 
0.021). Furthermore, the number of previous IUI attempts 
was significantly different among the 4 groups, with the 
post hoc analysis showing a significantly higher number of 
previous IUI attempts in the LTZ+300 group compared to 
tection of the spontaneous LH surge, following the hCG in-
jection. 
The semen samples were microscopically examined to 
determine sperm motility and concentration after 30 min-
utes of liquefaction at room temperature. Sperm samples 
for IUI were prepared by density gradient centrifugation. 
For the insemination process, a soft catheter (Wallace artifi-
cial insemination catheter, Smiths Medical, London, UK) 
was used to introduce 0.5 mL of the prepared semen into 
the uterine cavity. After insemination, luteal support was 
achieved with micronized progesterone vaginal supposito-
ries (Utrogestan, Cassenne-Aventis, Paris, France), 400 mg 
daily for 2 weeks.
The primary outcome measures were achievement of 
pregnancy, multiple pregnancy, and OHSS development. 
The secondary outcome measures were the size of the lead-
ing follicle, endometrial thickness on the day of hCG ad-
ministration, and number of growing and mature follicles. 
Clinical pregnancy was defined as the presence of an intra-
uterine gestational sac with a pulsating fetal heart beat on 
ultrasound. Multiple pregnancy was defined as the presence 
of >2 intrauterine gestational sacs with a pulsating fetal heart 
beat on ultrasound. OHSS was classified as mild, moderate, 
severe, and critical according to criteria described previous-
ly by Navot, et al.19
Data were analyzed using the SPSS software package, 
Table 1. Clinical Characteristics of Study Subjects
CC+300 (n=37) CC+450 (n=89) LTZ+300 (n=36) LTZ+450 (n=95) p value
Age of women (yrs) 33.13±4.37 34.61±3.63 34.69±3.82 34.62±3.41 0.162
Duration of infertility (months)   22.68±13.72   28.02±20.46   30.75±16.33   25.51±17.68 0.211
Baseline serum FSH (IU/L)     6.66±2.09*   7.49±2.80   7.06±2.93     8.75±3.81* 0.011
Previous IUI attempts (n)     0.21±0.48†,‡    0.55±0.80§    0.92±0.97†     1.20±1.14‡,§ <0.001
Primary vs. secondary (%) 0.322
    Primary infertility 25 (67.6) 60 (67.4)    20 (55.6) 69 (72.6)
    Secondary infertility 12 (32.4) 29 (32.6)    16 (44.4) 26 (27.4)
Causes (%) 0.240
    Unexplained 26 (70.3) 53 (59.6)    29 (80.6) 67 (70.6)
    Male   8 (21.6) 18 (20.2)    3 (8.3) 12 (12.6)
    Endometriosis 3 (8.1) 18 (20.2)      4 (11.1) 16 (16.8)
Tubal patency (%) 0.071
    Unilateral   6 (17.6) 12 (14.5) 1 (3) 6 (6.4)
    Bilateral 28 (82.4) 71 (85.5) 32 (97) 88 (93.6)
CC, clomiphene citrate; LTZ, letrozole; FSH, follicle-stimulating hormone; IUI, intrauterine insemination.
Values represent mean±SD. 
*, †,‡,§Post-hoc p<0.05 by Bonferroni’s multiple comparison test.
*CC300 vs. LTZ 450.
†CC300 vs. LTZ300.
‡CC300 vs. LTZ 450.
§CC450 vs. LTZ450.
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thickness on the day of hCG administration was significantly 
greater in the alternate-day regimen of 3 days compared to 
that of 2 days (8.77±2.11 mm vs. 9.62±1.94 mm, p=0.031). 
In the cycles using LTZ, the primary outcomes‒clinical preg-
nancy rate, multiple pregnancy rate, and development of 
OHSS‒and the secondary outcomes were similar between 
both alternate-day gonadotropin regimens (Table 3).
In the alternate-day gonadotropin regimen of 2 days, the 
primary and secondary outcomes were comparable be-
tween the CC+300 and LTZ+300 groups. However, the 
number of follicles in size of 11‒13 mm on the day of hCG 
administration was significantly higher in CC+300 group 
than LTZ+300 group (0.78±1.06 vs. 0.35±0.65, p=0.041). 
In the alternate gonadotropin regimen of 3 days, although 
there was no significant difference in the clinical pregnancy 
rate between the cycles using CC and LTZ, the endometrial 
thickness was significantly greater in the LTZ+450 group 
(9.62±1.94 mm vs. 10.14±1.79 mm, p=0.049). The number 
of follicles in size of 11‒13 mm on the day of hCG adminis-
tration was significantly higher in the CC+450 group than in 
the LTZ+450 group (0.99±1.34 vs. 0.54±0.89, p=0.009). The 
pre-preparation TMSC and post-preparation sperm concen-
trations were significantly higher in the LTZ+450 group than 
in the CC+450 group (106.12±130.06 vs. 152.57±142.91, 
p=0.024; 56.15±59.62 mL vs. 103.47±107.14 mL, p<0.001). 
OHSS was significantly more prevalent in the CC+450 group 
than in the LTZ+450 (12.4% vs. 1.1%, p=0.002). Finally, 
the multiple pregnancy rate was significantly higher in the 
the CC+300 group (0.21±0.48 vs. 0.92±0.97 months, p= 
0.008) and in the LTZ+450 group compared to the CC+450 
group (0.55±0.80 vs. 1.20±1.14, p<0.001) (Table 1). 
The clinical pregnancy rate, multiple pregnancy rate, and 
the development of OHSS per cycle in the study population 
were 15.2%, 20.5%, and 5.8%, respectively. The clinical 
pregnancy rate was comparable between the CC and LTZ 
groups (18.3% vs. 12.2%, p=0.177). Multiple pregnancies 
occurred in 2 cases in the CC group and 6 cases in the LTZ 
group (8.7% vs. 37.5%, p=0.028), for a total of 7 twin and 1 
triplet pregnancies. OHSS was significantly more prevalent 
in the CC group than in the LTZ group [13 cases (10.3%) 
vs. 2 cases (1.5%), p=0.003]. The size of the leading folli-
cle and the number of follicles with a mean diameter of ≥18 
mm on the day of hCG administration were comparable be-
tween the two groups. However, on the day of hCG admin-
istration, the number of follicles with a mean diameter 11‒13 
mm was significantly higher (0.93±1.27 vs. 0.49±0.83, 
p=0.001) and endometrial thickness was significantly lesser 
in the CC group (9.37±2.02 vs. 9.98±1.85, p=0.005) than 
the LTZ group. Although there was no difference in total 
motile sperm count (TMSC) before preparation between 
the two groups, the post-preparation sperm concentration 
was significantly higher in the LTZ group than in the CC 
group (Table 2).
In the cycles using CC, the primary and secondary out-
comes were comparable between the alternate-day gonado-
tropin regimens of 2 and 3 days. However, the endometrial 
Table 2. The Outcomes of Intrauterine Insemination Cycles Using Gonadotropin Combined with Clomiphene Citrate or Letro-
zole
CC (n=126) Letrozole (n=131) p value 
Size of the leading follicle (mm) 20.03±2.43 20.35±2.35 0.174
Number of follicles (n)
    11‒13 mm   0.93±1.27   0.49±0.83 0.001
    14‒16 mm   1.44±1.46   1.20±1.18 0.162
    ≥18 mm   1.44±0.88   1.53±0.89 0.432
ET at day of hCG administration (mm)   9.37±2.02   9.98±1.85 0.005
Pre-preparation TMSC   109.96±122.82   136.74±131.87 0.096
Post-preparation sperm concentration   56.86±60.68   90.25±99.53 0.003
Clinical pregnancy (%)   23 (18.3) 16 (12.2) 0.177
Multiple pregnancy (%)   2 (8.7)   6 (37.5) 0.028
Miscarriage (%)   2 (1.6) 1 (0.8) 0.071
OHSS (%)   13 (10.3) 2 (1.5) 0.003 
    Mild   3 (2.4) 1 (0.8) 
    Moderate 10 (7.9) 1 (0.8) 
CC, clomiphene citrate; ET, endometrial thickness; OHSS, ovarian hyperstimulation syndrome; TMSC, total motile sperm count; hCG, human chorionic go-
nadotropin.
Values represent mean±SD.
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with gonadotropin stimulation (cancellation rate, 1.2% vs. 
8.4%, respectively).29 In a prospective randomized study 
which compared conventional CC/hMG stimulation proto-
col to minimal stimulation protocol, the incidence of OHSS 
was 3% in conventional stimulation cycles whereas none of 
OHSS was developed in minimal stimulation cycles.10 Few-
er OHSS cases were observed in our study than in previous 
studies10,11 of IUI cycles with minimal stimulation. 
Interestingly, in our study, multiple pregnancies signifi-
cantly increased in cycles with the alternate-day regimens 
of 3 days, in LTZ users. Although it cannot be clearly ex-
plained, this significant difference may be due to superovu-
lation by combining gonadotropin and favorable endome-
trial receptivity by using LTZ without antiestrogenic effect 
on endometrium. LTZ itself has been suggested to develop 
less multiple pregnancies in ovulation induction for poly-
cystic ovary syndrome (PCOS) women.30 However, our 
study showed that superovulation combined with gonado-
tropin may increase multiple pregnancies. Recently, a large 
retrospective review of 2929 patients with unexplained infer-
tility showed that increasing number of mature follicles grad-
ually increased multiple pregnancies.31 Furthermore, contrary 
to CC, LTZ has no antiestrogenic effect on endometrium. 
Our study showed that minimal stimulation combined with 
LTZ increased endometrial thickness compared to that com-
bined with CC, which may indicate that the administration of 
CC cause hostile endometrium due to antiestrogenic effect 
on endometrium.
The current study showed that OHSS development was 
significantly lower in the LTZ group, independent of other 
LTZ+450 group than in the CC+450 group (50% vs. 13.3%, 
p=0.038) (Table 3).
DISCUSSION
The four different regimens in our study showed comparable 
clinical pregnancy rates per cycle. Minimal stimulation pro-
tocols using LTZ resulted in the development of fewer small 
follicles, with a similar number of medium- to large-sized 
follicles when compared to those using CC. As a result, the 
development of OHSS was more prevalent in CC users, es-
pecially combined with alternate-day gonadotropin 3 days 
regimen. Multiple pregnancies were more prevalent in the 
alternate-day gonadotropin regimen of 3 days, combined 
with LTZ, but not in the alternate-day gonadotropin regi-
mens of 2 days, neither in combination with CC, nor LTZ.
The clinical pregnancy and multiple pregnancy rates in the 
current study are comparable to those reported in previous 
studies.4,15,20-25 In large population observational studies26,27 
and a randomized controlled trial,4 although the clinical preg-
nancy rate per cycle was approximately 10% in IUI with 
gonadotropin only, multiple pregnancies represented 30% 
of these cases. In other studies, the multiple pregnancy rate 
after ovulation induction with gonadotropin varies between 
5% and 20%.4,23,25,28 In terms of OHSS, few studies have 
demonstrated the development of OHSS in IUI with con-
trolled ovarian stimulation cycles. In a prospective random-
ized trial, the cancellation rate was reported based on the 
OHSS risk, instead of the OHSS development rate in IUI 

















Diameter of the 
  leading follicle (mm) 
19.59±2.14 20.21±2.53 20.60±2.41 20.26±1.79 0.197 0.476 0.054 0.893
Endometrial thickness 
  (mm) 
  8.77±2.11   9.62±1.94   9.56±1.97 10.14±1.79 0.031 0.118 0.109 0.049
Number of follicles (n) 
    11‒13 mm   0.78±1.06   0.99±1.34   0.35±0.65   0.54±0.89 0.410 0.191 0.041 0.009
    14‒17 mm   1.19±1.20   1.54±1.55   0.97±0.97   1.29±1.24 0.222 0.181 0.403 0.225
    ≥18 mm   1.46±1.07   1.44±0.80   1.59±1.61   1.51±0.96 0.902 0.591 0.531 0.578
Pre-preparation TMSC   119.22±104.38  106.12±130.06   95.41±85.98   152.57±142.91 0.592 0.006 0.294 0.024
Post-preparation 
  sperm concentration 
  59.12±65.24   56.15±59.62   47.29±50.29   103.47±107.14 0.839 <0.001 0.468 <0.001
Clinical pregnancy (%)      8 (21.6) 15 (16.9)      4 (11.1) 12 (12.6) 0.528 0.812 0.226 0.419
Multiple pregnancy (%) 0 (0)   2 (13.3) 0 (0)   6 (50.0) 0.533 0.103 - 0.038
OHSS (%)    2 (5.4) 11 (12.4)    1 (2.8) 1 (1.1) 0.243 0.472 0.572 0.002
CC, clomiphene citrate; LTZ, letrozole; TMSC, total motile sperm count; OHSS, ovarian hyperstimulation syndrome; IUI, intrauterine insemination.
Minimal Stimulation Using Gonadotropin for IUI
Yonsei Med J   http://www.eymj.org   Volume 56   Number 2   March 2015 495
tioned. Firstly, since this was a retrospective study and not a 
randomized controlled trial, a selection bias or confounding 
factors may influence the results. However, the similarity in 
baseline clinical characteristics‒including age, duration of 
infertility, and causes of infertility‒suggest that the selection 
bias was minimal. Secondly, the sample size has limited sta-
tistical power for any conclusion to be drawn regarding the 
outcomes among 4 different groups. When a power calcula-
tion was performed using PS: Power and Sample size calcu-
lation software Version 3.0.43 (http://biostat.mc.vanderbilt.
edu/wiki/Main/PowerSampleSize), the sample size has the 
power of 27.5, 58.9, and 85.5% to detect a significant differ-
ence for clinical pregnancy rate, multiple pregnancy rate and 
the development of OHSS, respectively, between the CC 
group and the LTZ group. Regarding the development of 
OHSS, further studies in a larger scale will be necessary to 
confirm our results, although this study had sufficient power. 
In conclusion, a minimal stimulation protocol using LTZ 
combined with alternate-day administration of gonadotropin 
for 2 days seems to be efficacious for IUI, because it does not 
affect superovulation and clinical pregnancy rates, while re-
ducing multiple pregnancies and OHSS development. 
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